FadhlAlakwaa United States

Institution

Day 1 - Sunday April 14, 2024

Time	Session

9 a.m. 10:30 a.m.	Hands on Big Data Mining for the Nephrologist in 2024 SK1001 HeatherAscani Chairperson United StatesUniversity of Michigan KatherineTuttle Chairperson United StatesUniversity of Washington School of Medicine, Division of Nephrology MatthiasKretzler Chairperson United StatesUniversity of Michigan Looking for Data on Glomerular Diseases: How to Find the Treasures You Are Looking for With a Click of a Mouse VijiNair Speaker United StatesUniversity of Michigan Open Science in an Open Community: Resources of the Kidney Precision Medicine Project for CKD and AKI MatthiasKretzler Speaker United StatesUniversity of Michigan The Future is Now: How to Mine Cells and Neighborhoods of the Kidney in Health and Disease JulioSaez-Rodriguez Speaker julio.saez@uni-heidelberg.deGermanyHeidelberg University Panel Discussion Hall C1	Precise Phenotyping and Treatment SK01 HeatherReich Chairperson CanadaUniversity of Toronto, University Health Network SebastiánJaurretche Chairperson sebastianjaurretche@hotmail.comArgentinaSanatorio Parque SA Deciphering the IGAN Cell Atlas JulioSaez-Rodriguez Speaker julio.saez@uni-heidelberg.deGermanyHeidelberg University Complement-mediated Kidney Diseases in the Era of Complement Inhibitors MarinaVivarelli Speaker marina.vivarelli@opbg.netItalyLaboratory of Nephrology, Bambino Gesù Children's Hospital CART-T JonathanHogan Speaker jonathan.hogan@cabalettabio.comCabaletta Bio New Targets to Reduce the Burden of Rare Kidney Diseases LauraMariani Speaker lmariani@umich.eduUnited StatesUniversity of Michigan Q and A Hall C4
12 p.m. 1 p.m.	Big Data Lab 1 LAB-01 Big Data Lab
3 p.m. 4 p.m.	Big Data Lab 2 LAB-02 Big Data Lab	New Tools to Study Kidney Disease SK02 RafaelMaldonado Chairperson ramaldonado@gmail.comArgentina ReikoInagi Chairperson JapanThe University of Tokyo Graduate School of Medicine Understanding Glomerular Damage: From Spatial Transcriptomics to Chip Technology LauraPerin Speaker LPerin@chla.usc.eduUnited States Spatial Metabolomics of Kidney Disease TonRabelink Speaker a.j.rabelink@lumc.nlNetherlandsLUMC Constructing an Epigenetic Network for Diabetic Nephropathy Sam El-Osta Speaker sam.el-osta@baker.edu.auAustraliaBaker Heart and Diabetes Institute Q and A Hall E
5 p.m. 6 p.m.	Big Data Lab 3 LAB-03 Big Data Lab

Day 2 - Monday April 15, 2024

Time	Session

9 a.m. 10:30 a.m.	Insights From Understanding Heterogeneous Trajectories to Kidney Failure LF03 FacundoDaminato Chairperson fmdaminato@hotmail.comArgentina Magdalena Madero Chairperson MexicoChief of Nephrology, Instituto Nacional de Cardiol PietroRavani Chairperson pravani@ucalgary.caCanadaUniversity of Calgary Non-neoplastic Lesions in Nephrectomy Samples: Implications for Kidney Function JairMunoz Mendoza Speaker JMMendoza@med.miami.eduUnited StatesUniversity of Miami Understanding the Heterogeneous Trajectory of CKD MorganGrams Speaker morgan.grams@nyulangone.orgUnited StatesNew York University Review of Medical Therapies Proven to Delay CKD Progression DoreenZhu Speaker doreen.zhu@ndph.ox.ac.ukUnited KingdomUniversity of Oxford Impact of Obesity and Novel Treatment Strategies on CKD Progression PeterRossing Speaker DenmarkSteno Diabetes Center Copenhagen Q and A Hall C4
11 a.m. 12 p.m.	Plenary Session 3: Generative AI Revolution in Medicine (Michal Rosen-Zvi, Israel) PL3 Jose VicenteSanchez Polo Chairperson visanpolo@gmail.comGuatemalaRenal Division Social Security Institute. Nephrology Residence Program Coordinator, San Carlos University School of Medicine. Latin-American Society Of Nephrology (SLANH) MegJardine Chairperson AustraliaNHMRC Clinical Trials Centre, University of Sydney, Australia Generative AI Revolution in Medicine MichalRosen-Zvi Speaker ROSEN@il.ibm.comIsraelhttps://research.ibm.com/ Acceptance Speech by Awardee (Schrier Award), with Tasnuva Sarah Kashem (UK) and Farnaz Nobi (Bangladesh) Mohammad Shakib Uz ZamanArefin Speaker shakib04@yahoo.comBangladesh Hall A
12:15 p.m. 1:15 p.m.	The Journey of a Patient with Kidney and Cardiovascular Diseases: From Detection to Referral to Co-management IK1002 RobertoPecoits Filho Chairperson United StatesArbor Research Collaborative for Health Challenges in the Early Detection and Management of a Patient at the Interface of Kidney and Heart Disease MarisolTorres Toledano Speaker torres.t.marisol@gmail.comMexicoIMSS, MEXICO Co-management of Patients With Cardio-Kidney Diseases: Let DebasishBanerjee Speaker United KingdomSt George's University Hospital NHS Foundation Tr Co-management of Patients With Cardio-Kidney Diseases: Let CharlesHerzog Speaker Charles.Herzog@cdrg.orgUnited StatesISN and Hennepin Healthcare/University of Minnes Q and A Hall C1
12:45 p.m. 1:30 p.m.	Keys to success to be on top of what is published in nephrology (ISN-ACT) SPOT-15 AndreaViecelli Spotlight Speaker AustraliaUniversity of Queensland Augusto CesarSoares dos Santos Junior Spotlight Speaker BrazilHospital das Clinicas, UFMG; Fac Ciências Medicas BrendanSmyth Spotlight Speaker brendan.smyth@sydney.edu.auAustralia DavidWheeler Spotlight Speaker United KingdomUniversity College London MegJardine Spotlight Chairperson AustraliaNHMRC Clinical Trials Centre, University of Sydney, Australia Spotlight Stage 1 (exhibition hall)
3 p.m. 4 p.m.	Big Data Lab 5 LAB-05 Big Data Lab	Late Breaking Clinical Trials Session LBCT AlessiaFornoni Chairperson United StatesUniversity of Miami MichelleRheault Chairperson rheau002@umn.eduUnited StatesUniversity of Minnesota Predicting the Risks of Kidney Failure and Death in Adults With Moderate-to-severe Chronic Kidney Disease (KDpredict) PietroRavani Free Communication pravani@ucalgary.caCanadaUniversity of Calgary Plasma Exchange in ANCA Associated Vasculitis GN: Update After Pexivas Wladimir MietekSzpirt Speaker wladimir.mietek.szpirt.01@regionh.dkDenmarkRigshospitalet, University of Copenhagen, Dept. of Nephrology, Denmark, Senior Research Consultant EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY: INTERIM RESULTS FROM THE PHASE 3 APPLAUSE-IgAN STUDY DanaRizk Free Communication drizk@uabmc.eduUnited StatesUniversity of Alabama at Birmingham SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL JonathanBarratt Free Communication United KingdomUniversity of Leicester, Leicester, UK PREGNANCY AMONG WOMEN ON CHRONIC DIALYSIS : THE FRENCH COHORT CécileCouchoud Free Communication cecile.couchoud@biomedecine.frFranceREIN registry, Agence de la biomédecine, France Hall A
4:30 p.m. 5:30 p.m.	Designing Smart Clinical Trials SK05 DebbieGipson Chairperson debbie.gipson@nih.govUnited StatesNational Institutes of Health/NIDDK JonathanBarratt Chairperson United KingdomUniversity of Leicester, Leicester, UK Patients Subphenotyping: The Example of Diabetic Kidney Disease John CijiangHe Speaker cijiang.he@mssm.eduUnited StatesIcahn School of Medicine at Mount Sinai Power of AI to Develop Data-driven Early Detection, Diagnosis, and Management of Kidney Disease LauraMariani Speaker lmariani@umich.eduUnited StatesUniversity of Michigan Targeted Approaches in Clinical Trial Design HiddoLambers Heerspink Speaker H.J.Lambers.Heerspink@umcg.nlNetherlands Q and A Hall D
4:45 p.m. 5:30 p.m.	Implementing early CKD detection programs SPOT-19 AdeeraLevin Spotlight Speaker CanadaUniversity of British Columbia and Providence Health Care Jose VicenteSanchez Polo Spotlight Speaker visanpolo@gmail.comGuatemalaRenal Division Social Security Institute. Nephrology Residence Program Coordinator, San Carlos University School of Medicine. Latin-American Society Of Nephrology (SLANH) LauraSola Spotlight Speaker UruguayDialysis Center, CASMU-IAMPP VivekanandJha Spotlight Speaker IndiaGeorge Institute for Global Health India Spotlight Stage 1 (exhibition hall)
5 p.m. 6 p.m.	Big Data Lab 6 LAB-06 Big Data Lab

Day 3 - Tuesday April 16, 2024

Time	Session

9 a.m. 10 a.m.	Type 2 Diabetes in Kidney Disease: Recent Updates and Best Practices for Detection and Treatment LF1002 DebasishBanerjee Chairperson United KingdomSt George's University Hospital NHS Foundation Tr MegJardine Chairperson AustraliaNHMRC Clinical Trials Centre, University of Sydney, Australia Setting the Scene MegJardine Speaker AustraliaNHMRC Clinical Trials Centre, University of Sydney, Australia DM and CKD: Which Treatment Should I Use for Different Populations? KatherineTuttle Speaker United StatesUniversity of Washington School of Medicine, Division of Nephrology How to Design Studies on Answering Unanswered Questions VladoPerkovic Speaker AustraliaUniversity of New South Wales, Sydney, Australia The Effect of SGLT2 Inhibitors in Patients with Chronic Kidney Disease, With or Without Type 2 Diabetes DavidWheeler Speaker United KingdomUniversity College London Q and A Hall C4

Time

Session

9 a.m.

10 a.m.

Type 2 Diabetes in Kidney Disease: Recent Updates and Best Practices for Detection and Treatment

LF1002

DebasishBanerjee Chairperson United KingdomSt George's University Hospital NHS Foundation Tr

MegJardine Chairperson AustraliaNHMRC Clinical Trials Centre, University of Sydney, Australia

Setting the Scene

MegJardine Speaker AustraliaNHMRC Clinical Trials Centre, University of Sydney, Australia
DM and CKD: Which Treatment Should I Use for Different Populations?

KatherineTuttle Speaker United StatesUniversity of Washington School of Medicine, Division of Nephrology
How to Design Studies on Answering Unanswered Questions

VladoPerkovic Speaker AustraliaUniversity of New South Wales, Sydney, Australia
The Effect of SGLT2 Inhibitors in Patients with Chronic Kidney Disease, With or Without Type 2 Diabetes

DavidWheeler Speaker United KingdomUniversity College London
Q and A

Hall C4